<DOC>
	<DOCNO>NCT02555943</DOCNO>
	<brief_summary>This prospective study determine incidence , morbidity , mortality predispose factor reactivation hepatitis B virus replication direct anti-HCV treatment HCV/HBV co-infection patient .</brief_summary>
	<brief_title>DAAs Treatment Chronic HCV/HBV Co-infection Patients ( DASCO )</brief_title>
	<detailed_description>Patients receive direct-acting anti-HCV treatment prospectively study 2-year period . All patient HCV/HBV co-infection . The inclusion/exclusion criterion follow plan list following part .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Hepatitis C Antibodies</mesh_term>
	<criteria>HCV RNA positive , HBsAg positive detectable undetectable HBV DNA , Receiving pan oral directacting antiHCV regimen Pregnant nurse female male pregnant female partner ; HIV infection ; Hematologic biochemical parameter Screening outside protocol specify requirement ; Active recent history ( â‰¤ 1 year ) drug alcohol abuse ; History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere subject 's participation full duration study , best interest subject participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>